Resources
About Us
Home Report
Store
Cancer/Tumor Profiling Market
Cancer/Tumor Profiling Market Size, Share, Forecast, & Trends Analysis by Biomarker Type (Genetic, Protein) Technology (NGS, PCR, ISH) Cancer Type (Breast, Prostate) Application (Clinical, Research) End User (Pharma, Academic) - Global Forecast to 2031
Report ID:MRHC - 104947 Pages: 270 Oct-2024 Formats*: PDF Category: Healthcare Delivery: 24 to 48 HoursCancer/Tumor Profiling Market Size & Forecast
The Cancer/Tumor Profiling Market is projected to reach $24.70 billion by 2031 at a CAGR of 10.9% from 2024 to 2031. The rise in cancer cases, the growing research of novel molecules, and the increasing number of genomic research projects have increased the demand for cancer/tumor profiling. The emergence of tumor profiling has removed the restraints of traditional cancer/tumor classification approaches, which rely on the morphology of the cancerous cells and the surrounding tissues. Today, cancer/tumor profiling is accepted as the standard technique for classifying tumors, with the guidelines associated with the European Society for Molecular Oncology (ESMO) and the College of American Pathologists (CAP).
The profiling of tumors with advanced technologies such as ISH, NGS, IHC, and PCR has successfully analyzed the genes, amplicons, and gene regions with familiar involvement with tumors. This approach, also known as targeted treatment, delivers high sensitivity for detecting tumor subclones or rare mutations, providing increased visibility regarding important mutations acting as drivers of cancer.
The growth of the cancer/tumor profiling market is attributed to the increasing prevalence of cancer, the rising pharmaceutical R&D expenditures, the growing number of targeted therapies and the discovery of new actionable biomarkers, increasing investments in cancer research, the declining costs of NGS-based profiling, and advancements in multi-omics tumor profiling. However, the high capital investments required for NGS setups and long turnaround times restrain the growth of this market.
Additionally, the increasing focus on developing personalized medicines and the rising awareness and adoption of targeted therapies are expected to generate market growth opportunities. However, the lack of genetic experts for interpreting results, the non-availability of in-house tumor profiling technologies, and the high number of false biomarker discoveries are major challenges for the stakeholders in the cancer/tumor profiling market.
Cancer/Tumor Profiling Market Growth Drivers
Advancements in Multi-omics Tumor Profiling and Cancer Research
Cancer research has benefited from the advancement in omics technologies from genomics to transcriptomics and from a wide variety of resources obtained from multiple omics datasets originating from the patients. Multi-omics approaches offer a unique opportunity to identify cancer patients' clinical and molecular features. In transcriptomics and genomics, there is an unmet need to distinguish between inconsistency in related biological procedures, like differences in variability or post-translational changes in the expression profiles due to the role of mRNA transcripts in the development of cancer.
Recent advancements in proteomics have facilitated the emergence of proteogenomic approaches. These approaches seamlessly integrate genomic data with proteomics data, including insights into post-translational modifications such as acetylation and protein phosphorylation. These developments in multi-omics tumor profiling and cancer research are expected to drive the growth of the cancer/tumor profiling market.
Click here to: Get Free Sample Pages of this Report
Increasing Prevalence of Cancer
The burden of cancer is growing globally. According to GLOBOCAN 2020, cancer incidence is expected to increase from 19.3 million in 2020 to 30.2 million in 2040. Moreover, the mortality due to cancer is estimated to increase from 9.9 million in 2020 to 16.3 million in 2040. Nearly 70% of the total deaths due to cancer occur in low and middle-income countries. Early detection is extremely important in reducing mortality, improving patients’ chances of survival, and saving on treatment costs. Various methods are used to detect cancer. The demand for cancer/tumor profiling for cancer diagnosis is expected to grow significantly in the coming years.
Advancements in Multi-omics Tumor Profiling
During the last decade, genomics and proteomics approaches have become effective and crucial tools in the clinical research of biological pathways involved in cancer pathogen replication, host response, and disease progression. Genomics and proteomics are important for discovering and understanding host-pathogen interactions. They offer the opportunity to improve personalized treatments and disease prevention in advanced cancer cases. Genomics primarily aims to sequence, assemble, and analyze the functions and structures of genomes. At the same time, proteomics helps in the large–scale study of the complete set of proteins within an organism. Such developments in genomics and proteomics are expected to drive the cancer/tumor profiling market.
Cancer/Tumor Profiling Market Opportunity
Increasing Focus on the Development of Personalized Medicines Creating Market Growth Opportunities
Personalized/precision medicine uses an individual’s genomic information to offer targeted treatment. The synthesis of genes can rapidly sequence large sections of a person’s genome and aid in the formulation of precision medicine, in turn generating cost-effective alternatives to existing therapies and allowing for novel treatments. Personalized medicine analyzes molecules, individual genes, and networks and translates them into an overall output for the systems of the human body. These medicines can tailor therapies with the best responses and highest safety margins, ensuring better patient care. Moreover, precision medicines help cure diseases and enhance the chances of saving people undergoing treatments for life-threatening diseases. Furthermore, cancer treatment and diagnosis are also advancing significantly with the increased adoption of advanced technologies such as PCR, NGS, FISH, and ISH in precision medicine.
New targeted cancer treatments that use genomic data to provide patient-specific treatments are known as precision oncology. This rapidly developing field has already become a part of mainstream clinical practices. It involves the molecular profiling of cancer cells to identify targetable alterations, also known as biomarkers. Quick and reliable sequencing of multiple genes at once is possible with next–generation sequencing (NGS) technology. Furthermore, personalized medicine contributes to advancements in new therapies for cancer treatment, the development of new methods for disease detection, and the development of preventive medicines. Thus, the increasing inclination toward personalized medicine-based diagnosis and treatment is expected to create opportunities for market growth.
Cancer/Tumor Profiling Market Analysis: Key Findings
Based on Biomarker Type, the Genetic Biomarkers Segment is Expected to Account for the Largest Share of the Market in 2024
Based on biomarker type, the cancer/tumor profiling market is segmented into genetic biomarkers and protein biomarkers. In 2024, The genetic biomarkers segment is expected to account for the largest share of 72.0% of the cancer/tumor profiling market. The large market share of this segment is attributed to the benefits offered by genetic biomarkers, including their reliability in identifying drug-resistant cancer cells, assisting in identifying genetic patterns responsible for future cancer recurrence, and their increased use for the early detection of cancer.
Based on Technology, the Next-Generation Sequencing (NGS) Segment is Expected to Account for the Largest Share of the Market in 2024
Based on technology, the cancer/tumor profiling market is segmented into next-generation sequencing (NGS), polymerase chain reaction (PCR), in situ hybridization (ISH), immunohistochemistry (IHC), and other technologies. In 2024, the next-generation sequencing (NGS) segment is expected to account for the largest share of the cancer/tumor profiling market. The large market share of this segment is attributed to the benefits offered by NGS, such as high-throughput production, efficient instrument runs, and cost-effectiveness compared to traditional first-generation sequencing methods. Additionally, NGS is highly preferred for large-scale genomic profiling and transcriptomic sequencing.
Based on Cancer Type, the Breast Cancer Segment is Expected to Account for the Largest Share of the Market in 2024
Based on Cancer Type, the cancer/tumor profiling market is segmented into breast cancer, colorectal cancer, lung cancer, prostate cancer, lymphoma, leukemia, cervical cancer, and other cancer types. In 2024, The breast cancer segment is expected to account for the largest share of the cancer/tumor profiling market. The large market share of this segment is attributed to the rising incidence of breast cancer cases and the increasing adoption of tumor profiling for breast cancer.
Based on Application, the Research Applications Segment is Expected to Account for the Largest Share of the Market in 2024
Based on application, the cancer/tumor profiling market is segmented into clinical applications and research applications. In 2024, the research applications segment is expected to account for the largest share of the cancer/tumor profiling market. The large market share of this segment is attributed to the decreasing cost of sequencing procedures, the rising research and development efforts by pharmaceutical and biopharmaceutical companies in drug and biomarker discovery, the high sensitivity and throughput offered by advanced profiling technology, and the expanding applications of cancer/tumor profiling in various clinical and research areas.
Based on End User, the Pharmaceutical & Biopharmaceutical Companies Segment is Expected to Account for the Largest Share of the Market in 2024
Based on End User, the cancer/tumor profiling market is segmented into pharmaceutical & biopharmaceutical companies, hospitals & diagnostic laboratories, academic & research institutes, and contract research organizations (CROs). In 2024, the pharmaceutical & biopharmaceutical companies segment is expected to account for the largest share of 40.9% of the cancer/tumor profiling market. The large market share of this segment is attributed to the declining costs of sequencing, the increase in research and development activities by pharmaceutical and biopharmaceutical companies, and the extensive utilization of advanced profiling solutions for cancer studies.
Geographical Analysis
In 2024, North America is expected to account for the largest share of 42.7% of the cancer/tumor profiling market. North America’s significant market share can be attributed to the high prevalence of cancer, substantial healthcare expenditure, widespread adoption of advanced molecular technologies, and substantial investment in pharmaceutical R&D.
Cancer/Tumor Profiling Market: Key Companies
The report offers a competitive landscape based on an extensive assessment of the product offerings and geographic presence of leading market players and the key growth strategies adopted by them over the past few years (2021–2024). The key players operating in the global cancer/tumor profiling market are Thermo Fisher Scientific Inc. (U.S.), Illumina, Inc. (U.S.), QIAGEN N.V. (Netherlands), F. Hoffmann-La Roche Ltd. (Switzerland), Agilent Technologies, Inc. (U.S.), NanoString Technologies, Inc. (U.S.), HTG Molecular Diagnostics, Inc. (U.S.), Agendia Inc. (U.S.), Personalis, Inc. (U.S.), Exact Sciences Corporation (U.S.), and Tempus Labs, Inc. (U.S.).
Cancer/Tumor Profiling Industry Overview: Latest Developments from Key Industry Players
- In May 2023, Thermo Fisher Scientific Inc. (U.S.) launched the Orbitrap Astral mass spectrometer, which combines high sensitivity, fast throughput, and deep proteome coverage, allowing researchers to identify new clinical biomarkers and develop new interventions from cardiovascular disease to cancer.
- In March 2023, Thermo Fisher Scientific Inc. (U.S.) collaborated with Arsenal Biosciences, Inc. (U.S.), a clinical-stage cell therapy company operating in solid tumor therapies for developing advanced manufacturing processes for new cancer treatments.
- In March 2023, Illumina, Inc. (U.S.) partnered with Myriad Genetics, Inc. (U.S.) to expand the partnership for broadening the accessibility and availability of oncology homologous recombination deficiency (HRD) testing in the U.S. This partnership also opened new doors for companion diagnostic (CDx) alliance for the pharmaceutical industry, enabling clinical research in gene-based and targeted therapies.
- In September 2022, Illumina, Inc. (U.S.) launched its NovaSeq 6000 Dx, the first FDA-registered and CE-marked in vitro diagnostic (IVD) high-throughput sequencer, along with Illumina Complete Long-Reads, XLEAP-SBS Chemistry, NextSeq 1000/2000 Roadmap, and NovaSeq X Series (NovaSeq X and NovaSeq X Plus).
Cancer/Tumor Profiling Market Research Summary
|
Particulars |
Details |
|
Number of Pages |
270 |
|
Format |
|
|
Forecast Period |
2024-2031 |
|
Base Year |
2023 |
|
CAGR |
10.9% |
|
Estimated Market Size (Value) |
$24.70 billion by 2031 |
|
Segments Covered |
By Biomarker Type
By Technology
By Application
By Cancer Type
By End User
|
|
Countries Covered |
North America (U.S. and Canada), Europe (Germany, France, U.K., Italy, Spain, and Rest of Europe), Asia-Pacific (Japan, China, India, and Rest of Asia-Pacific), Latin America and Middle East & Africa |
|
Key Companies |
The key players operating in the global cancer/tumor profiling market are Thermo Fisher Scientific Inc. (U.S.), Illumina, Inc. (U.S.), QIAGEN N.V. (Netherlands), F. Hoffmann-La Roche Ltd. (Switzerland), Agilent Technologies, Inc. (U.S.), NanoString Technologies, Inc. (U.S.), HTG Molecular Diagnostics, Inc. (U.S.), Agendia Inc. (U.S.), Personalis, Inc. (U.S.), Exact Sciences Corporation (U.S.), and Tempus Labs, Inc. (U.S.). |
Key questions answered in the cancer/tumor profiling market report:
The global cancer/tumor profiling market report covers the qualitative analysis and market sizing of biomarker type, cancer type, technology, application, and end user. This report involves the analysis of various segments of cancer/tumor profiling at the regional and country level. The report also provides insights on factors impacting market growth, factor analysis, case studies, regulatory analysis, pricing analysis, and Porter’s five forces analysis.
The cancer/tumor profiling market is projected to reach $24.70 billion by 2031, at a CAGR of 10.9% during the forecast period.
Among the biomarkers covered in this report, the genetic biomarkers segment is expected to account for the largest share of the market in 2024.
Among the technologies covered in this report, the next-generation sequencing (NGS) segment is expected to account for the largest share of the market in 2024. The large market share of this segment is attributed to the higher sensitivity of this technique compared to call variants, low sequencing costs compared to other sequencing technologies, and the availability of low-cost sequencers.
Among the cancer types covered in the report, the breast cancer segment is expected to account for the largest share of the market in 2024. The increase in breast cancer cases, government initiatives promoting breast cancer treatment, increasing healthcare expenditure, and reimbursement for certain profiling technologies such as NGS drive the demand for cancer/tumor profiling for breast cancer.
Among the applications covered in this report, the research applications segment is expected to hold the largest share of the market in 2024. The large market share of this segment is attributed to the rising incidence of cancer, the growing demand for precision medicine, the increased discovery of biomarkers, and the availability of cost-effective advanced profiling technologies like NGS and PCR within research protocols.
Among the end users covered in this report, the pharmaceutical & biopharmaceutical companies segment is expected to hold the largest share of the market in 2024. The large market share of this segment is attributed to rising research efforts in biomarker discovery, the growing demand for precision medicine, and the increasing number of cancer studies aimed at advancing cancer treatment.
The growth of the cancer/tumor profiling market is attributed to the increasing prevalence of cancer, the rising pharmaceutical R&D expenditures, the growing number of targeted therapies and the discovery of new actionable biomarkers, increasing investments in cancer research, the declining costs of NGS-based profiling, and advancements in multi-omics tumor profiling.
Furthermore, the increasing focus on developing personalized medicines and the rising awareness and adoption of targeted therapies are expected to generate market growth opportunities.
The key players profiled in the cancer/tumor profiling market study are Thermo Fisher Scientific Inc. (U.S.), Illumina, Inc. (U.S.), QIAGEN N.V. (Netherlands), F. Hoffmann-La Roche Ltd. (Switzerland), Agilent Technologies, Inc. (U.S.), NanoString Technologies, Inc. (U.S.), HTG Molecular Diagnostics, Inc. (U.S.), Agendia Inc. (U.S.), Personalis, Inc. (U.S.), Exact Sciences Corporation (U.S.), and Tempus Labs, Inc. (U.S.).
Emerging economies such as China and India are projected to offer significant growth opportunities to the market players due to rising investments in the healthcare sector and increasing genomic projects in these countries.
1. Introduction
1.1. Market Definition and Scope
1.2. Market Ecosystem
1.3. Currency and Limitation
1.4. Key Stakeholders
2. Research Methodology
2.1. Research Approach
2.2. Process of Data Collection and Validation
2.2.1. Secondary Research
2.2.2. Primary Research/Interviews with Key Opinion Leaders of the Industry
2.3. Market Sizing and Forecast
2.3.1. Market Size Estimation Approach
2.3.2. Growth Forecast Approach
2.3.3. Market Share Analysis
2.4. Assumptions for the Study
3. Executive Summary
4. Market Insights
4.1. Overview
4.2. Market Insights
4.2.1. Impact Analysis of Market Dynamics
4.2.2. Factor Analysis
4.3. Regulatory Analysis
4.3.1. North America
4.3.1.1. U.S.
4.3.1.1. Japan
4.3.1.1. India
4.3.1.2. Canada
4.3.2. Europe
4.3.3. Asia-Pacific
4.3.3.1. China
4.3.3.2. Japan
4.3.3.3. India
4.3.4. Latin America
4.3.5. Middle East
4.4. Porter's Five Forces Analysis
4.4.1. Bargaining Power of Buyers
4.4.2. Bargaining Power of Suppliers
4.4.3. Threat of Substitutes
4.4.4. Threat of New Entrants
4.4.5. Degree of Competition
5. Cancer/Tumor Profiling Market Assessment—by Biomarker Type
5.1. Overview
5.2. Genetic Biomarkers
5.3. Protein Biomarkers
6. Cancer/Tumor Profiling Market Assessment—by Cancer Type
6.1. Overview
6.2. Breast Cancer
6.3. Colorectal Cancer
6.4. Lung Cancer
6.5. Prostate Cancer
6.6. Lymphoma
6.7. Leukemia
6.8. Cervical Cancer
6.9. Other Cancer Types
7. Cancer/Tumor Profiling Market Assessment—by Technology
7.1. Overview
7.2. Next-Generation Sequencing (NGS)
7.3. Polymerase Chain Reaction (PCR)
7.4. In Situ Hybridization (ISH)
7.5. Immunohistochemistry (IHC)
7.6. Other Technologies
8. Cancer/Tumor Profiling Market Assessment—by Application
8.1. Overview
8.2. Research Applications
8.3. Clinical Applications
9. Cancer/Tumor Profiling Market Assessment—by End User
9.1. Overview
9.2. Pharmaceutical & Biopharmaceutical Companies
9.3. Hospitals & Diagnostic Laboratories
9.4. Academic & Research Institutes
9.5. Contract Research Organizations (CROs)
10. Cancer/Tumor Profiling Market Assessment—by Geography
10.1. Overview
10.2. North America
10.2.1. U.S.
10.2.2. Canada
10.3. Europe
10.3.1. Germany
10.3.2. France
10.3.3. U.K.
10.3.4. Italy
10.3.5. Spain
10.3.6. Rest of Europe
10.4. Asia-Pacific
10.4.1. China
10.4.2. Japan
10.4.3. India
10.4.4. Rest of Asia-Pacific
10.5. Latin America
10.6. Middle East & Africa
11. Competition Analysis
11.1. Overview
11.2. Key Growth Strategies
11.3. Competitive Benchmarking
11.4. Market Share Analysis (2023)
11.4.1. Thermo Fisher Scientific Inc. (U.S.)
11.4.2. Illumina, Inc. (U.S.)
11.4.3. F. Hoffmann-La Roche Ltd (Switzerland)
11.4.4. Exact Sciences Corporation (U.S.)
11.4.5. Qiagen N.V. (Netherlands)
11.5. Competitive Dashboard
11.5.1. Industry Leaders
11.5.2. Market Differentiators
11.5.3. Vanguards
11.5.4. Emerging Companies
12. Company Profiles (Business Overview, Financial Overview, Product Portfolio, Strategic Developments, and SWOT Analysis*)
12.1. Thermo Fisher Scientific, Inc.
12.2. Illumina, Inc.
12.3. Qiagen N.V.
12.4. F. Hoffmann-La Roche Ltd
12.5. Exact Sciences Corporation
12.6. Agilent Technologies, Inc.
12.7. NanoString Technologies, Inc.
12.8. HTG Molecular Diagnostics, Inc.
12.9. Agendia Inc.
12.10. Personalis, Inc.
12.11. Tempus Labs, Inc.
(Note: SWOT analyses of the top 5 companies will be provided.)
13. Appendix
13.1. Available Customization
13.2. Related Reports
List of Tables
Table 1 Major Targeted Therapies and Corresponding Biomarkers
Table 2 Number of New Cancer Cases, by Type, 2020 Vs. 2030
Table 3 Regulatory Authorities Governing In Vitro Diagnostics, by Country/Region
Table 4 Global Cancer/Tumor Profiling Market, by Biomarker Type, 2022–2031 (USD Million)
Table 5 Germline Mutations in Hereditary Cancer Syndromes: Cancer-Causing Genes as Biomarkers of Risk
Table 6 Global Cancer/Tumor Profiling Market for Genetic Biomarkers, by Country/Region, 2022–2031 (USD Million)
Table 7 Global Cancer/Tumor Profiling Market for Protein Biomarkers, by Country/Region, 2022–2031 (USD Million)
Table 8 Global Cancer/Tumor Profiling Market, by Cancer Type, 2022–2031 (USD Million)
Table 9 Number of New Breast Cancer Cases Globally (2020–2035)
Table 10 Global Cancer/Tumor Profiling Market for Breast Cancer, by Country/Region, 2022–2031 (USD Million)
Table 11 Global Cancer/Tumor Profiling Market for Colorectal Cancer, by Country/Region, 2022–2031 (USD Million)
Table 12 Global Cancer/Tumor Profiling Market for Lung Cancer, by Country/Region, 2022–2031 (USD Million)
Table 13 Number of New Prostate Cancer Cases (2020–2035)
Table 14 Global Cancer/Tumor Profiling Market for Prostate Cancer, by Country/Region, 2022–2031 (USD Million)
Table 15 Number of New Non-Hodgkin Lymphoma Cancer Cases (2020–2035)
Table 16 Global Cancer/Tumor Profiling Market for Lymphoma, by Country/Region, 2022–2031 (USD Million)
Table 17 Estimated Number of New Leukemia Cases (2020–2035)
Table 18 Global Cancer/Tumor Profiling Market for Leukemia, by Country/Region, 2022–2031 (USD Million)
Table 19 Global Cancer/Tumor Profiling Market for Cervical Cancer, by Country/Region, 2022–2031 (USD Million)
Table 20 Number of New Cancer Cases (2020-2035)
Table 21 Global Cancer/Tumor Profiling Market for Other Cancer Types, by Country/Region, 2022–2031 (USD Million)
Table 22 Global Cancer/Tumor Profiling Market, by Technology, 2022–2031 (USD Million)
Table 23 Global Next–Generation Sequencing (NGS) Cancer/Tumor Profiling Market, by Country/Region, 2022–2031 (USD Million)
Table 24 Global Polymerase Chain Reaction (PCR) Cancer/Tumor Profiling Market, by Country/Region, 2022–2031 (USD Million)
Table 25 Global In Situ Hybridization Cancer/Tumor Profiling Market, by Country/Region, 2022–2031 (USD Million)
Table 26 Applications of IHC in Oncology and Related Antibodies
Table 27 Global Immunohistochemistry (IHC) Cancer/Tumor Profiling Market, by Country/Region, 2022–2031 (USD Million)
Table 28 Global Other Technologies Cancer/Tumor Profiling Market, by Country/Region, 2022–2031 (USD Million)
Table 29 Global Cancer/Tumor Profiling Market, by Application, 2022–2031 (USD Million)
Table 30 Currently Available Targeted Therapies and Corresponding Biomarkers
Table 31 Global Cancer/Tumor Profiling Market for Research Applications, by Country/Region, 2022–2031 (USD Million)
Table 32 Frequently Used Clinical Tumor Markers
Table 33 Global Cancer/Tumor Profiling Market for Clinical Applications, by Country/Region, 2022–2031 (USD Million)
Table 34 Global Cancer/Tumor Profiling Market, by End User, 2022–2031 (USD Million)
Table 35 Global Cancer/Tumor Profiling Market for Pharmaceutical & Biopharmaceutical Companies, by Country/Region, 2022–2031 (USD Million)
Table 36 Global Cancer/Tumor Profiling Market for Hospitals & Diagnostic Laboratories, by Country/Region, 2022–2031 (USD Million)
Table 37 Global Cancer/Tumor Profiling Market for Academic & Research Institutes, by Country/Region, 2022–2031 (USD Million)
Table 38 Global Cancer/Tumor Profiling Market for CROs, by Country/Region, 2022–2031 (USD Million)
Table 39 Global Cancer/Tumor Profiling Market, by Region, 2022–2031 (USD Million)
Table 40 Estimated Cancer Cases in North America: 2020–2030
Table 41 North America: Cancer/Tumor Profiling Market, by Country, 2022–2031 (USD Million)
Table 42 North America: Cancer/Tumor Profiling Market, by Biomarker Type, 2022–2031 (USD Million)
Table 43 North America: Cancer/Tumor Profiling Market, by Technology, 2022–2031 (USD Million)
Table 44 North America: Cancer/Tumor Profiling Market, by Cancer Type, 2022–2031 (USD Million)
Table 45 North America: Cancer/Tumor Profiling Market, by Application, 2022–2031 (USD Million)
Table 46 North America: Cancer/Tumor Profiling Market, by End User, 2022–2031 (USD Million)
Table 47 U.S.: Key Macro & Micro Indicators
Table 48 U.S.: Cancer/Tumor Profiling Market, by Biomarker Type, 2022–2031 (USD Million)
Table 49 U.S.: Cancer/Tumor Profiling Market, by Technology, 2022–2031 (USD Million)
Table 50 U.S.: Cancer/Tumor Profiling Market, by Cancer Type, 2022–2031 (USD Million)
Table 51 U.S.: Cancer/Tumor Profiling Market, by Application, 2022–2031 (USD Million)
Table 52 U.S.: Cancer/Tumor Profiling Market, by End User, 2022–2031 (USD Million)
Table 53 Canada: Key Macro & Micro Indicators
Table 54 Canada: Cancer/Tumor Profiling Market, by Biomarker Type, 2022–2031 (USD Million)
Table 55 Canada: Cancer/Tumor Profiling Market, by Technology, 2022–2031 (USD Million)
Table 56 Canada: Cancer/Tumor Profiling Market, by Cancer Type, 2022–2031 (USD Million)
Table 57 Canada: Cancer/Tumor Profiling Market, by Application, 2022–2031 (USD Million)
Table 58 Canada: Cancer/Tumor Profiling Market, by End User, 2022–2031 (USD Million)
Table 59 Europe: Cancer/Tumor Profiling Market, by Country, 2022–2031 (USD Million)
Table 60 Europe: Cancer/Tumor Profiling Market, by Biomarker Type, 2022–2031 (USD Million)
Table 61 Europe: Cancer/Tumor Profiling Market, by Technology, 2022–2031 (USD Million)
Table 62 Europe: Cancer/Tumor Profiling Market, by Cancer Type, 2022–2031 (USD Million)
Table 63 Europe: Cancer/Tumor Profiling Market, by Application, 2022–2031 (USD Million)
Table 64 Europe: Cancer/Tumor Profiling Market, by End User, 2022–2031 (USD Million)
Table 65 Germany: Key Macro & Micro Indicators
Table 66 Germany: Cancer/Tumor Profiling Market, by Biomarker Type, 2022–2031 (USD Million)
Table 67 Germany: Cancer/Tumor Profiling Market, by Technology, 2022–2031 (USD Million)
Table 68 Germany: Cancer/Tumor Profiling Market, by Cancer Type, 2022–2031 (USD Million)
Table 69 Germany: Cancer/Tumor Profiling Market, by Application, 2022–2031 (USD Million)
Table 70 Germany: Cancer/Tumor Profiling Market, by End User, 2022–2031 (USD Million)
Table 71 France: Key Macro & Indicators
Table 72 France: Cancer/Tumor Profiling Market, by Biomarker Type, 2022–2031 (USD Million)
Table 73 France: Cancer/Tumor Profiling Market, by Technology, 2022–2031 (USD Million)
Table 74 France: Cancer/Tumor Profiling Market, by Cancer Type, 2022–2031 (USD Million)
Table 75 France: Cancer/Tumor Profiling Market, by Application, 2022–2031 (USD Million)
Table 76 France: Cancer/Tumor Profiling Market, by End User, 2022–2031 (USD Million)
Table 77 U.K.: Key Macro & Micro Indicators
Table 78 U.K.: Cancer/Tumor Profiling Market, by Biomarker Type, 2022–2031 (USD Million)
Table 79 U.K.: Cancer/Tumor Profiling Market, by Technology, 2022–2031 (USD Million)
Table 80 U.K.: Cancer/Tumor Profiling Market, by Cancer Type, 2022–2031 (USD Million)
Table 81 U.K.: Cancer/Tumor Profiling Market, by Application, 2022–2031 (USD Million)
Table 82 U.K.: Cancer/Tumor Profiling Market, by End User, 2022–2031 (USD Million)
Table 83 Italy: Key Macro & Micro Indicators
Table 84 Italy: Cancer/Tumor Profiling Market, by Biomarker Type, 2022–2031 (USD Million)
Table 85 Italy: Cancer/Tumor Profiling Market, by Technology, 2022–2031 (USD Million)
Table 86 Italy: Cancer/Tumor Profiling Market, by Cancer Type, 2022–2031 (USD Million)
Table 87 Italy: Cancer/Tumor Profiling Market, by Application, 2022–2031 (USD Million)
Table 88 Italy: Cancer/Tumor Profiling Market, by End User, 2022–2031 (USD Million)
Table 89 Spain: Key Macro & Micro Indicators
Table 90 Spain: Cancer/Tumor Profiling Market, by Biomarker Type, 2022–2031 (USD Million)
Table 91 Spain: Cancer/Tumor Profiling Market, by Technology, 2022–2031 (USD Million)
Table 92 Spain: Cancer/Tumor Profiling Market, by Cancer Type, 2022–2031 (USD Million)
Table 93 Spain: Cancer/Tumor Profiling Market, by Application, 2022–2031 (USD Million)
Table 94 Spain: Cancer/Tumor Profiling Market, by End User, 2022–2031 (USD Million)
Table 95 Estimated Number of New Cancer Cases, by Country, 2020 Vs. 2030
Table 96 Rest of Europe: Cancer/Tumor Profiling Market, by Biomarker Type, 2022–2031 (USD Million)
Table 97 Rest of Europe: Cancer/Tumor Profiling Market, by Technology, 2022–2031 (USD Million)
Table 98 Rest of Europe: Cancer/Tumor Profiling Market, by Cancer Type, 2022–2031 (USD Million)
Table 99 Rest of Europe: Cancer/Tumor Profiling Market, by Application, 2022–2031 (USD Million)
Table 100 Rest of Europe: Cancer/Tumor Profiling Market, by End User, 2022–2031 (USD Million)
Table 101 Asia-Pacific: Cancer/Tumor Profiling Market, by Country/Region, 2022–2031 (USD Million)
Table 102 Asia-Pacific: Cancer/Tumor Profiling Market, by Biomarker Type, 2022–2031 (USD Million)
Table 103 Asia-Pacific: Cancer/Tumor Profiling Market, by Technology, 2022–2031 (USD Million)
Table 104 Asia-Pacific: Cancer/Tumor Profiling Market, by Cancer Type, 2022–2031 (USD Million)
Table 105 Asia-Pacific: Cancer/Tumor Profiling Market, by Application, 2022–2031 (USD Million)
Table 106 Asia-Pacific: Cancer/Tumor Profiling Market, by End User, 2022–2031 (USD Million)
Table 107 China: Key Macro & Micro Indicators
Table 108 China: Cancer/Tumor Profiling Market, by Biomarker Type, 2022–2031 (USD Million)
Table 109 China: Cancer/Tumor Profiling Market, by Technology, 2022–2031 (USD Million)
Table 110 China: Cancer/Tumor Profiling Market, by Cancer Type, 2022–2031 (USD Million)
Table 111 China: Cancer/Tumor Profiling Market, by Application, 2022–2031 (USD Million)
Table 112 China: Cancer/Tumor Profiling Market, by End User, 2022–2031 (USD Million)
Table 113 Japan: Key Macro & Micro Indicators
Table 114 Japan: Cancer/Tumor Profiling Market, by Biomarker Type, 2022–2031 (USD Million)
Table 115 Japan: Cancer/Tumor Profiling Market, by Technology, 2022–2031 (USD Million)
Table 116 Japan: Cancer/Tumor Profiling Market, by Cancer Type, 2022–2031 (USD Million)
Table 117 Japan: Cancer/Tumor Profiling Market, by Application, 2022–2031 (USD Million)
Table 118 Japan: Cancer/Tumor Profiling Market, by End User, 2022–2031 (USD Million)
Table 119 India: Key Macro & Micro Indicators
Table 120 India: Cancer/Tumor Profiling Market, by Biomarker Type, 2022–2031 (USD Million)
Table 121 India: Cancer/Tumor Profiling Market, by Technology, 2022–2031 (USD Million)
Table 122 India: Cancer/Tumor Profiling Market, by Cancer Type, 2022–2031 (USD Million)
Table 123 India: Cancer/Tumor Profiling Market, by Application, 2022–2031 (USD Million)
Table 124 India: Cancer/Tumor Profiling Market, by End User, 2022–2031 (USD Million)
Table 125 Estimated Number of New Cancer Cases, by Country, 2020 Vs. 2030
Table 126 Rest of Asia-Pacific: Cancer/Tumor Profiling Market, by Biomarker Type, 2022–2031 (USD Million)
Table 127 Rest of Asia–Pacific: Cancer/Tumor Profiling Market, by Technology, 2022–2031 (USD Million)
Table 128 Rest of Asia–Pacific: Cancer/Tumor Profiling Market, by Cancer Type, 2022–2031 (USD Million)
Table 129 Rest of Asia–Pacific: Cancer/Tumor Profiling Market, by Application, 2022–2031 (USD Million)
Table 130 Rest of Asia–Pacific: Cancer/Tumor Profiling Market, by End User, 2022–2031 (USD Million)
Table 131 Latin America: Cancer/Tumor Profiling Market, by Biomarker Type, 2022–2031 (USD Million)
Table 132 Latin America: Cancer/Tumor Profiling Market, by Technology, 2022–2031 (USD Million)
Table 133 Latin America: Cancer/Tumor Profiling Market, by Cancer Type, 2022–2031 (USD Million)
Table 134 Latin America: Cancer/Tumor Profiling Market, by Application, 2022–2031 (USD Million)
Table 135 Latin America: Cancer/Tumor Profiling Market, by End User, 2022–2031 (USD Million)
Table 136 Middle East & Africa: Cancer/Tumor Profiling Market, by Biomarker Type, 2022–2031 (USD Million)
Table 137 Middle East & Africa: Cancer/Tumor Profiling Market, by Technology, 2022–2031 (USD Million)
Table 138 Middle East & Africa: Cancer/Tumor Profiling Market, by Cancer Type, 2022–2031 (USD Million)
Table 139 Middle East & Africa: Cancer/Tumor Profiling Market, by Application, 2022–2031 (USD Million)
Table 140 Middle East & Africa: Cancer/Tumor Profiling Market, by End User, 2022–2031 (USD Million)
Table 141 Recent Developments, by Company, 2021-2024
List of Figures
Figure 1 Research Process
Figure 2 Secondary Sources Referenced for This Study
Figure 3 Primary Research Techniques
Figure 4 Key Executives Interviewed
Figure 5 Breakdown of Primary Interviews (Supply-Side & Demand-Side)
Figure 6 Market Sizing and Growth Forecast Approach
Figure 7 Global Cancer/Tumor Profiling Market, by Biomarker Type, 2024 Vs. 2031
Figure 8 Global Cancer/Tumor Profiling Market, by Technology, 2024 Vs. 2031 (USD Million)
Figure 9 Global Cancer/Tumor Profiling Market, by Cancer Type, 2024 Vs. 2031
Figure 10 Global Cancer/Tumor Profiling Market, by Application, 2024 Vs. 2031
Figure 11 Global Cancer/Tumor Profiling Market, by End User, 2024 Vs. 2031
Figure 12 Global Cancer/Tumor Profiling Market, by Geography
Figure 13 Global Cancer/Tumor Profiling Market: Impact Analysis of Market Drivers, Restraints, Opportunities, and Challenges (2024–2031)
Figure 14 Number of Cancer Cases, by Region, 2020
Figure 15 Pharmaceutical R&D Expenditures in The U.S., Europe, And China, 2010 Vs. 2019 Vs. 2020 (USD Million)
Figure 16 Global Pharmaceutical R&D Expenditure, 2012–2026 (USD Billion)
Figure 17 Percentage of Approved Personalized Medicines, by Disease, 2022
Figure 18 Percentage of FDA Approvals for Personalized Medicines, 2015–2022
Figure 19 Percentage of Oncology Trials Incorporating Biomarkers, 2000–2019
Figure 20 Global Increase in The Number of Personalized Medicines, 2008–2020
Figure 21 USFDA Regulatory Pathways for IVD Kits
Figure 22 EU Regulatory Pathway - IVDR 2017/746
Figure 23 China: Medical Device Classification and Premarket Requirements for Cancer/Tumor Profiling Products
Figure 24 Porter's Five Forces Analysis
Figure 25 Global Cancer/Tumor Profiling Market, by Biomarker Type, 2024 Vs. 2031 (USD Million)
Figure 26 Global Cancer/Tumor Profiling Market, by Cancer Type 2024 Vs. 2031 (USD Million)
Figure 27 Global Cancer/Tumor Profiling Market, by Technology, 2024 Vs. 2031 (USD Million)
Figure 28 Global Cancer/Tumor Profiling Market, by Application, 2024 Vs. 2031 (USD Million)
Figure 29 FDA Approvals for Personalized Medicine (%) (2015–2021)
Figure 30 Global Cancer/Tumor Profiling Market, by End User, 2024 Vs. 2031 (USD Million)
Figure 31 Global Pharmaceutical R&D Spending, 2014–2028 (USD Billion)
Figure 32 Global Cancer/Tumor Profiling Market, by Geography, 2024 Vs. 2031 (USD Million)
Figure 33 North America Cancer/Tumor Profiling Market Snapshot
Figure 34 U.S.: Pharmaceutical R&D Expenditure, 2014–2021 (USD Billion)
Figure 35 Europe: Pharmaceutical Industry R&D Expenditure (2000–2021)
Figure 36 Europe: Cancer/Tumor Profiling Market Snapshot
Figure 37 U.K: Number of Cancer Cases, 2010–2030 (In Million)
Figure 38 Italy: Ovarian Cancer Diagnoses (2018–2020)
Figure 39 Italy: Number of Biotechnology Firms, 2010-2021
Figure 40 Rest of Europe: Pharmaceutical R&D Expenditure, 2020
Figure 41 Asia-Pacific: Cancer/Tumor Profiling Market Snapshot
Figure 42 Japan: New Cancer Cases Reported (2020–2040)
Figure 43 Latin America: Estimated Number of New Cancer Cases (2020–2030)
Figure 44 Middle East & Africa: Number of New Cancer Cases, by Country/Region (2020)
Figure 45 Key Growth Strategies Adopted by Leading Players, 2021– 2024
Figure 46 Cancer/Tumor Profiling Market: Competitive Benchmarking by Offering
Figure 47 Cancer/Tumor Profiling Market: Competitive Benchmarking by Technology
Figure 48 Cancer/Tumor Profiling Market: Competitive Benchmarking, by Region
Figure 49 Global Cancer/Tumor Profiling Market Share Analysis, by Key Players, 2023 (%)
Figure 50 Competitive Dashboard: Cancer/Tumor Profiling Market
Figure 51 Thermo Fisher Scientific, Inc.: Financial Overview (2023)
Figure 52 Illumina, Inc.: Financial Overview (2023)
Figure 53 Qiagen N.V.: Financial Overview (2023)
Figure 54 F. Hoffmann-La Roche Ltd: Financial Overview (2023)
Figure 55 Exact Sciences Corporation: Financial Overview (2023)
Figure 56 Agilent Technologies, Inc.: Financial Overview (2023)
Figure 57 NanoString Technologies, Inc.: Financial Overview (2023)
Figure 58 HTG Molecular Diagnostics, Inc.: Financial Overview (2023)
Figure 59 Personalis, Inc.: Financial Overview (2023)
Proudly Partnering With Enterprises Around the Globe
Quick Contact
Related Reports
Europe Cancer Diagnostics Market- Opportunity Analysis And Industry Forecast (2024-2031)
Published Date: Feb-2024
Point of care Diagnostics Market - Global Opportunity Analysis and Industry Forecast (2023-2030)
Published Date: May-2023
Tissue Diagnostics Market - Global Opportunity Analysis and Industry Forecast (2022-2029)
Published Date: Nov-2022
HLA Typing Market - Global Opportunity Analysis And Industry Forecast (2022-2029)
Published Date: Oct-2022
North America Tissue Diagnostics Market - Opportunity Analysis and Industry Forecast (2024-2030)
Published Date: Jun-2024
